Literature DB >> 18671327

Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha.

Richard E Kast, Eric L Altschuler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18671327

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  3 in total

1.  Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System.

Authors:  Allison Salk; Derrick J Stobaugh; Parakkal Deepak; Eli D Ehrenpreis
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

2.  Relative expression and correlation of tumor necrosis factor-α, interferon-γ, and interleukin-17 in the rheumatoid synovium.

Authors:  Arata Nakajima; Yasuchika Aoki; Masato Sonobe; Fusako Watanabe; Hiroshi Takahashi; Masahiko Saito; Koichi Nakagawa
Journal:  Clin Rheumatol       Date:  2016-04-01       Impact factor: 2.980

3.  Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and Its soluble receptors during the course of therapy with etanercept and infliximab.

Authors:  Martin Schulz; Helmut Dotzlaw; Gunther Neeck
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.